

March 2015 Appendix 4C

Melbourne, Australia, 29 April 2015

Prescient Therapeutics Limited (“**Prescient**” or “**the Company**”) provides the following Appendix 4C in relation to the quarter ended 31 March 2015.

During the quarter, Prescient obtained an exclusive worldwide license for intellectual property rights to a novel cancer biomarker known as p27 from Lee Moffitt Cancer Center in the United States, negotiated on favourable terms.

Prescient was also granted key patents that underpin the development and commercialization of its lead drug candidate PTX-200, strengthening its portfolio and providing broader coverage of the use of its PTX-200 drug in combination studies.

The Company was also invited to present at the prestigious 27th Annual Roth Conference, providing a unique opportunity to showcase the company to the US investment market.

During the quarter, the Company changed Company Secretary and relocated its offices to Melbourne.

Cash at the end of the quarter, as detailed in the attached Appendix 4C, was approximately \$1.477 million. The two clinical trials currently underway for PTX-200 in breast cancer and ovarian cancer remain funded by US government grants.

About Prescient Therapeutics

Prescient Therapeutics is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

Lead drug candidate PTX-200 inhibits an important tumor survival pathway known as AKT, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukaemia. This highly promising compound is now the focus of two current clinical trials. The first is a Phase 1b/2 study of PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York. The second is also a Phase 1b/2 trial in patients with recurrent or persistent platinum resistant ovarian cancer at Florida’s Lee Moffitt Cancer Center. In addition, Prescient is planning a Phase 1b/2 trial evaluating PTX-200 as a new therapy for acute myeloid leukemia in 2015.

Prescient’s second novel drug candidate, PTX-100, is a first in class compound with the ability to block important cancer-causing proteins such as Ral and Rho, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase 1 trial in advanced solid tumors. Prescient expects to commence Phase 1b/2 clinical trials in breast cancer and multiple myeloma in 2015. At the same time, Prescient plans to develop its novel p27 cancer biomarker as a companion diagnostic that will potentially identify those patients that are most likely to respond to PTX-100 therapy.

Prescient has licensed access to its Co-X-Gene™ platform technology to French biotechnology company Transgene for use in two immunotherapeutic products.

Contact:

Dr Robert Crombie (Managing Director)

Ms Melanie Leydin (Company Secretary)

Ph: +61 (0) 3 9692 7222



Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005, 17/12/2010

Name of entity

Prescient Therapeutics Limited (Formerly Virax Holdings Limited)

ABN

56 006 569 106

Quarter ended ("current quarter")

31 March 2015

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date (9 months) \$A'000
1.1 Receipts from customers	-	-
1.2 Payments for:		
(a) staff costs	(68)	(200)
(b) advertising and marketing	(67)	(118)
(c) research and development	(320)	(714)
(d) leased assets	-	-
(e) other working capital	(390)	(956)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	7	37
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Other items		
(a) Net GST (paid to)/recovered from ATO	-	-
(b) R & D tax rebate received	-	-
(c) Government grant received	-	-
(d) R&D contract contributions received	-	-
Net operating cash flows	(838)	(1,951)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

	Current quarter \$A'000	Year to date (9 months) \$A'000
1.8 Net operating cash flows (carried forward)	(838)	(1,951)
Cash flows related to investing activities		
1.9 Payment for acquisition of:		
(a) businesses (item 5)	-	(364)
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.10 Proceeds from disposal of:	-	-
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.11 Loans to other entities	-	-
1.12 Loans repaid by other entities	-	-
1.13 Other (provide details if material)	-	-
Net investing cash flows	-	(364)
1.14 Total operating and investing cash flows	-	(2,315)
Cash flows related to financing activities		
1.15 Proceeds from issues of shares, options, etc.	-	-
1.16 Proceeds from sale of forfeited shares	-	-
1.17 Proceeds from borrowings	-	-
1.18 Repayment of borrowings	-	-
1.19 Dividends paid	-	-
1.20 Capital raising costs	-	-
Net financing cash flows	-	-
Net increase (decrease) in cash held	(838)	(2,315)
1.21 Cash at beginning of quarter/year to date	2,309	3,786
Exchange rate adjustments to item 1.20	6	6
1.23 Cash at end of quarter	1,477	1,477

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	152
1.25	Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

Directors' fees and Executive Directors' salaries paid during the March 2014 quarter. This includes fees that were due to the Directors in the December 2014 quarter.

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

-

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

-

Financing facilities available

Add notes as necessary for an understanding of the position.

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	-	-
3.2	Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	1,477	2,309
4.2 Deposits at call	-	-
4.3 Bank overdraft	-	-
4.4 Other (provide details)	-	-
Total: cash at end of quarter (item 1.23)	1,477	2,309

Acquisitions and disposals of business entities

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1 Name of entity	-	-
5.2 Place of incorporation or registration	-	-
5.3 Consideration for acquisition or disposal	-	-
5.4 Total net assets	-	-
5.5 Nature of business	-	-

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here: 

 (Company Secretary)

Date: 29 April 2015

Print name: Melanie Leydin

+ See chapter 19 for defined terms.

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirement requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms.